At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 244 enrolled
Drug / intervention
MIV-711 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind Placebo-controlled Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of MIV-711 in Knee Joint Osteoarthritis
In Brief
A Phase 2 clinical trial evaluating MIV-711 and Placebo for Osteoarthritis, Knee. Completed, enrolled 244 participants across 6 sites in 6 countries.
Detailed Summary
This is a multicentre, randomised, placebo-controlled, double-blind, three-arm parallel, Phase IIa study to evaluate the efficacy, safety and tolerability of MIV-711 in patients with knee osteoarthritis (OA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Knee
CountriesBulgaria, Georgia, Germany, Moldova, Romania, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJan 2016
First PostedMar 2016
Primary CompletionMay 2017
TodayJul 2026
First PostedMar 10, 2016
Enrollment StartJan 28, 2016
Primary CompletionMay 23, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.3 years ago
Interventions
MIV-711drug
MIV-711 administered orally once daily
Placebodrug
Placebo manufactured to mimic MIV-711 capsule.